Breast cancer treatment might offer protection against Alzheimer's disease, with a study of 70,000 survivors showing lower ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the. On June 4, the company published pre-specified analyses for its ...

The Oxalosis and Hyperoxaluria Foundation (OHF) has accepted UCSF Health into its OHF Care Center Network recognizing the health system’s dedication to providing high-quality medical care, resources, ...

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

If you take OTC proton pump inhibitors (PPIs), you could be among the uncounted. Familiar brands include Prilosec (omeprazole ...

Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

The FDA's breakthrough devices program helps the industry with faster review times, but the benefit to patients is unclear.

Unicycive, which was seeking approval of oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, said the FDA issued a so-called complete response letter ...

Unicycive Therapeutics Inc (NASDAQ:UNCY) saw its shares plunge 26% in early trading after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the company’s ...